Sanofi SA has synthesized new cyclopropane-aryl and vinyloxy-aryl compounds acting as transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) and/or WW domain-containing transcription regulator protein 1 (WWTR1; TAZ)/TEAD interaction inhibitors potentially useful for the treatment of cancer.

Pfizer Inc. has synthesized substituted fused heteroaryl lactam compounds acting as dual calcitonin (CALCR; CT-R)/amylin receptor agonists potentially useful for the treatment of obesity and type 2 diabetes.

Sironax Ltd. has disclosed new NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors potentially useful for the treatment of Parkinson’s disease, multiple sclerosis, traumatic brain injury, diabetic neuropathy, Alzheimer’s disease, Huntington’s disease, hereditary neuropathies, and stroke.

Several Sanofi SA patents divulge new mitogen-activated protein kinase 7 (MAPK7; ERK5) inhibitors potentially useful for the treatment of cancer.

Vivozon Inc. has identified new heterocyclic dual 5-HT2A/dopamine D2 receptor antagonists potentially useful for the treatment of schizophrenia.

Gilead Sciences Inc. has reported new protein arginine N-methyltransferase 5 (PRMT5) inhibitors potentially useful for the treatment of cancer.

Phrontline Biopharma (Hangzhou) Co. Ltd. has prepared and tested bispecific antibody-drug conjugates (bsADCs) comprising a bispecific antibody targeting B7 homolog 3 (B7-H3; CD276) and EGFR (HER1; erbB1) linked to a cytotoxic drug. They are described as potentially useful for the treatment of cancer.

Shanghai Allink Biotherapeutics Co. Ltd. has discovered new bispecific antibody-drug conjugates comprising a bispecific monoclonal antibody linked to a cytotoxic drug potentially useful for the treatment of cancer.

Dewpoint Therapeutics Inc. has patented new β-catenin (CTNNB1) condensate modulators potentially useful for the treatment of cancer.